

AdV5/AdV26 COVID vaccine and thrombosis biomarkers

1 **The impact of Gam-COVID-Vac, an AdV5/AdV26 COVID-19 vaccine, on the biomarkers of**
2 **endothelial function, coagulation and platelet activation.**

3
4 Anar Turmukhambetova^{1¶}, Sergey Yegorov^{2,3¶}, Ilya Korshukov¹, Valentina Barkhanskaya¹, Svetlana
5 Kolesnichenko¹, Dmitriy Klyuyev¹, Zhibek Zhumadilova¹, Aruzhan Pralieva¹, Laylim Absaghit¹, Ruslan
6 Belyaev⁴, Dmitriy Babenko¹, Gonzalo H. Hortelano³, Matthew S. Miller², Dmitriy Vazenmiller^{*1} and Irina
7 Kadyrova^{*1}.

8
9 ¹ Research Centre, Karaganda Medical University, Karaganda, Kazakhstan.

10 ² Michael G. DeGroote Institute for Infectious Disease Research; McMaster Immunology Research
11 Centre; Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON,
12 Canada.

13 ³ School of Sciences and Humanities, Nazarbayev University, Astana, Kazakhstan.

14 ⁴ Department of Neurology, Psychiatry and Rehabilitology, Karaganda Medical University, Kazakhstan.

15
16 *** Corresponding authors' contact emails:**

17 ikadyrova@qmu.kz, (IK)

18 dvazenmiller.qmu@gmail.com, (DV)

19
20 **¶ These authors contributed equally to this work (AT and SY)**

21

22

23

24

25

26

AdV5/AdV26 COVID vaccine and thrombosis biomarkers

27 **Key words:** COVID-19; SARS-CoV-2; Sputnik-V; Gam-COVID-Vac; vaccination; endothelial
28 activation; platelet activation; coagulation

29 **Abstract**

30 **Background:** COVID-19 vaccines have played a critical role in controlling the COVID-19 pandemic.

31 Although overall considered safe, COVID-19 vaccination has been associated with rare but severe

32 thrombotic events, occurring mainly in the context of adenoviral vectored vaccines. A better

33 understanding of mechanisms underlying vaccine-induced hypercoagulability and prothrombotic state is

34 needed to improve vaccine safety profile.

35 **Methods:** We assessed changes to the biomarkers of endothelial function (endothelin, ET-1), coagulation

36 (thrombomodulin, THBD and plasminogen activator inhibitor, PAI) and platelet activation (platelet

37 activating factor, PAF, and platelet factor 4 IgG antibody, PF4 IgG) within a three-week period after the

38 first (prime) and second (boost) doses of Gam-Covid-Vac, an AdV5/AdV26-vectored COVID-19

39 vaccine. Blood plasma collected from vaccinees (n=58) was assayed using ELISA assays. Participants

40 were stratified by prior COVID-19 exposure based on their baseline SARS-CoV-2-specific serology

41 results.

42 **Results:** We observed a significant post-prime increase in circulating ET-1, with levels sustained after the

43 boost dose compared to baseline. ET-1 elevation following dose 2 was most pronounced in vaccinees

44 without prior COVID-19 exposure. Prior COVID-19 was also associated with a mild increase in post-

45 dose 1 PAI.

46 **Conclusions:** Vaccination was associated with elevated ET-1 up to day 21 after the second vaccine dose,

47 while no marked alterations to other biomarkers, including PF4 IgG, were seen. A role of persistent

48 endothelial activation following COVID-19 vaccination warrants further investigation.

49

AdV5/AdV26 COVID vaccine and thrombosis biomarkers

50

51 **Introduction**

52 COVID-19 vaccination has been associated with rare, but life-threatening, venous and arterial thrombotic
53 events, with and without thrombocytopenia [1, 2]. Most reported thrombosis cases have been associated
54 with the widely used adenoviral vectored vaccines, such as the ChAdOx1 CoV-19 vaccine (AstraZeneca,
55 the University of Oxford) and the Ad26.COV2.S vaccine (Janssen; Johnson & Johnson) [1,2]. More
56 recently, a fatal case of vaccine-induced immune thrombocytopenia and thrombosis (VITT) was reported
57 after the receipt of the Gam-COVID-Vac (“Sputnik-V”, manufactured by the Gamaleya Research
58 Institute of Epidemiology and Microbiology) vaccine in a 24-year-old woman, with the onset of
59 symptoms on day 7 post-vaccination [3].

60 Although several haematological biomarkers have been linked to the VITT syndrome, including platelet
61 number, d-dimer, fibrinogen, and platelet factor 4 (PF4)-specific immunoglobulin G (IgG), the exact
62 mechanisms underlying vaccine-induced hypercoagulability and prothrombotic state remain enigmatic
63 [1,2]. Recent studies conducted predominantly in Europe in general vaccinee cohorts have identified
64 changes to clotting activation and endothelial function associated with the transient pro-inflammatory
65 post-vaccination state[4-7]. Further investigation of these changes in the context of less well-studied
66 vaccines such as the Gam-COVID-Vac, accounting for vaccination timing and prior natural exposure to
67 SARS-CoV-2, is vital for refining vaccine strategies and enhancing their safety and efficacy globally.

68 The Gam-COVID-Vac vaccine is a recombinant adenovirus (rAd) vectored vaccine, typically
69 administered in two doses containing rAd26 as a prime and rAd5 as a boost, with a 21-day interval
70 between the doses. Since late 2020, the vaccine has been deployed in 71 countries across Latin America,
71 Africa, and Asia, including Kazakhstan. Between February and September 2021, the mass COVID-19
72 vaccination campaign in Kazakhstan relied primarily of Gam-COVID-Vac, with >85% of vaccinated
73 subjects having received Sputnik-V [8]. During this massive vaccine rollout, we conducted a prospective
74 study of safety, reactogenicity and immunologic responses to Gam-COVID-Vac in a cohort with and

AdV5/AdV26 COVID vaccine and thrombosis biomarkers

75 without prior history of COVID-19 exposure [9].

76 Following our earlier studies of “Sputnik-V” [9], here, we explored the effects of the vaccine on
77 endothelial function, coagulation, and platelet activation and thus assessed changes to circulating
78 endothelin (ET-1), thrombomodulin (THBD), plasminogen activator inhibitor (PAI), platelet activating
79 factor (PAF) and PF4 IgG at three time points before and at 21 days following the prime and boost doses.

80

81 **Materials and Methods.**

82 **Study setting.**

83 The current analysis is a follow-up to an earlier observational prospective study of safety and
84 reactogenicity of Gam-COVID-Vac in Kazakhstan. Venous blood samples were collected on after fasting
85 at the same time in the morning. Due to a limited sample availability, only a subset of samples from the
86 earlier study was analyzed. Briefly, the main study was conducted in Central Kazakhstan, where ~60% of
87 the population had had confirmed exposure to SARS-CoV-2 by Spring 2021 [9-11]. Participants were
88 recruited at the Karaganda Medical University in April-May 2021 (ClinicalTrials.gov #NCT04871841)
89 and consisted of asymptomatic adults who had not previously received a COVID-19 vaccine; individuals
90 with respiratory symptoms or a laboratory-confirmed COVID-19 diagnosis within two weeks prior to the
91 study were excluded. Short questionnaires were administered to gather information on participants'
92 demographic background and recent history of COVID-19 exposure. At follow-up, participants were
93 screened for respiratory symptoms and tested for COVID-19; participants with COVID-19 at follow-up
94 were excluded. Gam-COVID-Vac administration (0.5 ml dose of vaccine injected into the deltoid muscle)
95 followed the national guidelines and was conducted after sample collection. The vaccine consisted of two
96 doses: the first dose contained rAd26, and the second dose contained rAd5. Each dose contained 1 ± 0.5
97 $\times 10^{11}$ rAd particles.

98 Based on serologic spike (S) IgG and IgA results, "no prior COVID-19" was defined as negative for both
99 S-IgG and -IgA (IgG-, IgA-). The "no prior COVID-19" group was defined as positive for either or both

AdV5/AdV26 COVID vaccine and thrombosis biomarkers

100 IgG and/or IgA (IgG+/-, IgA+/-) at baseline.

101 **Biomarker assays.**

102 All ELISA assays were performed on blood plasma using commercially available ELISA kits (Cloud
103 Clone Corp., China) for ET-1 (#CEA482Hu), PAI-1 (#SEA532Hu), TMBM (#SEA529Ca), PF4 IgG
104 (#AEK505Hu) and PAF (#CEA526Ge) following the manufacturer protocol. Paired vaccinee samples
105 were assayed on the same ELISA plate to avoid the effects of inter-plate variability. Absorbance was
106 measured at OD450 nm using the Evolis 100 ELISA reader (Bio-Rad).

107 **Statistical analyses.**

108 All analyses and graphing were performed in JASP 0.17.2.1 and Prism 9.5.1 software. We used the
109 Wilcoxon Signed Rank Test to assess differences across the time points, while differences between the
110 Prior and No Prior COVID-19 groups were assessed using Mann-Whitney U or Pearson's Chi-squared
111 tests. Since ET-1 and PAF assays use the competitive inhibition principle, the OD values for these
112 biomarkers were inverted prior to analysis by subtraction from the highest measured OD within each
113 assay. Other assay OD values were analyzed without any transformation.

114 **Role of the funding source**

115 The funders had no role in study design, data collection and analysis, decision to publish, or preparation
116 of the manuscript.

117 118 **Results**

119 We analyzed a total of 58 plasma samples paired across three study visits (baseline, post-dose 1 and post-
120 dose 2) that were available from the original clinical trial. The serologically confirmed presence of S-IgG
121 and/or S-IgA was used to stratify the participants by prior COVID-19 as previously.

122 There were no demographic or biometric differences between the Prior/No Prior COVID-19 subgroups
123 within the current study subset (Table 1). Due to the limited and variable sample availability, fewer

AdV5/AdV26 COVID vaccine and thrombosis biomarkers

124 samples were available for some of the assays, such as for PAF.

125 **Table 1.** Characteristics of study participants.

Characteristic	Overall, N = 58	No prior COVID-19, N = 23	Prior COVID- 19, N = 35	p-value^a
Age, years, median (IQR)	44.0 (37.3, 54.5)	44.0 (37.5, 53.5)	45.0 (38.0,54.0)	0.849
Male sex, n (%)	22 (37.9%)	16 (45.7%)	6 (26.1%)	0.132
Kazakh ethnicity, n (%)	35 (60.3%)	12 (52.2%)	23 (65.7%)	0.302
BMI, kg/m ² , median (IQR)	25.1 (22.8, 27.6)	23.7 (22.3, 27.5)	25.3 (23.9, 27.7)	0.210
Any comorbidities ^b	30 (51.7%)	12 (52.2%)	18 (51.4%)	0.665

126

127 ^a Differences between the Prior and No Prior COVID-19 groups were assessed using Mann-Whitney U or
128 Pearson's Chi-squared tests.

129 ^b Comorbidities consisted of self-reported gastrointestinal conditions, hypertension, chronic heart disease,
130 chronic obstructive pulmonary disease, history of malignancy, diabetes, liver disease, thyroid dysfunction,
131 kidney disease, neurologic conditions, autoimmune conditions; the distribution of individual
132 comorbidities did not differ between the “no prior COVID-19” and “prior COVID-19” groups.

133 In the main analysis (Fig 1), unstratified by prior COVID-19 exposure, ET-1 was the only marker

AdV5/AdV26 COVID vaccine and thrombosis biomarkers

134 significantly impacted by vaccination. ET-1 was significantly increased post-dose 1 ($p=0.002$), and this
135 increase was sustained post-dose 2 compared to baseline ($p=0.013$).

136
137 **Fig 1.** Impact of GamCovidVac vaccination on the blood biomarkers in all participants. A) Endothelin,
138 ET-1 (n=45). B) Thrombomodulin, THBD (n=51). C) Plasminogen activator inhibitor, PAI (n=49). D)
139 Platelet activating factor, PAF (n=27). E) Platelet factor 4 IgG antibody, PF4 IgG (n=50). Each dot
140 denotes a study participant, dashed lines link samples paired across the study visits. Gray boxes denote
141 median OD at each visit. OD: optic density. Statistical significance was assessed by the Wilcoxon Signed
142 Rank Test.

143 In the analysis stratified by prior COVID-19 exposure (Fig 2), ET-1 was elevated post-vaccination in both
144 prior and no prior COVID-19 groups, although this increase was not sustained in the prior COVID-19
145 group post-dose 2.

146
147
148 **Fig 2.** Impact of GamCovidVac vaccination on the blood biomarkers stratified by prior exposure to
149 COVID-19. A) Endothelin, ET-1 (n=16 and 29). B) Thrombomodulin, THBD (n=17 and 34). C)
150 Plasminogen activator inhibitor, PAI (n=16 and 33). D) Platelet activating factor, PAF (n=8 and 9). E)
151 Platelet factor 4 IgG antibody, PF4 IgG (n=17 and 33). Each dot denotes a study participant, dashed lines
152 link samples paired across the study visits. Gray boxes denote median OD at each visit. OD: optic
153 density. Statistical significance was assessed by the Wilcoxon Signed Rank Test.

154 Lastly, a mild post-dose 1 increase ($p=0.027$) was observed for PAI only in the prior COVID-19 group.

155

156 **Discussion**

157 Here we studied the impact of Gam-COVID-Vac on endothelial function, coagulation, and platelet

AdV5/AdV26 COVID vaccine and thrombosis biomarkers

158 activation biomarkers within a three-week period after the first and second vaccine doses. Vaccination
159 significantly increased ET-1 levels after the first dose, and this elevation was sustained after the second
160 dose. Furthermore, post-dose 2 ET-1 elevation was most pronounced in vaccinees without prior COVID-
161 19 exposure. Prior COVID-19 was also associated with a mild increase in post-dose 1 PAI. Consistent
162 with earlier studies [4,12], no marked alterations to other biomarkers, including PF4 IgG, were seen.
163 To the best of our knowledge, our study is the first to assess thrombosis-associated biomarkers in the
164 context of Gam-COVID-Vac vaccination. The current lack of studies on this aspect of "Sputnik-V" is
165 partly explained by a shortage of data on the vaccine's safety and performance outside of Russia, where
166 the vaccine originated [13]. At the same time, the reported cases of VITT and myocarditis after the receipt
167 of Gam-Covid-Vac have raised concerns about the under-reporting of vaccine-associated vascular events
168 [3,14]. Our current findings support the data from both human and animal studies [5,13,15] that
169 replication-deficient adenovirus vectored vaccines can trigger endothelial activation, which could
170 potentially induce platelet aggregation and thrombosis.
171 ET-1, a potent vasoconstrictor produced by the vascular endothelium, is a key regulator of vascular tone
172 and has been implicated in several cardiovascular diseases and in the pathogenesis of severe COVID-19
173 [16,17]. An increase in ET-1 level may therefore suggest a disturbance in endothelial function following
174 vaccination. In support of this, studies of ChAdOx-1 have found elevated post-vaccination levels of Von
175 Willebrand Factor, another biomarker of endothelial function [5].
176 Interestingly, when stratifying the data by prior COVID-19 exposure, we noticed a mild increase in PAI
177 levels in the prior COVID-19 group following the first vaccine dose. PAI is a primary inhibitor of
178 fibrinolysis and higher levels may hint towards an increased coagulation state, which is also observed in
179 COVID-19 [2]. This finding suggests that individuals with prior COVID-19 exposure might exhibit a
180 more pronounced coagulation response after the first vaccine dose, possibly due to a more robust immune
181 response triggered by the recognition of the SARS-CoV-2 S protein in the vaccine.
182 Our study has several limitations, including the limited and variable sample availability, that precluded us
183 from assaying more biomarkers. Our study cohort was also small and restricted to adults from Central

AdV5/AdV26 COVID vaccine and thrombosis biomarkers

184 Kazakhstan, limiting the generalizability of our findings. The observed changes to ET-1 and PAI, while
185 statistically significant, were mild and their clinical significance is yet to be fully understood. Future
186 studies with larger sample sizes and a more diverse population are needed to validate these findings and
187 elucidate the clinical implications. Additionally, studies exploring other potential factors such as age, sex,
188 comorbidities, and genetic predispositions that might influence these biomarker changes are warranted.
189 Despite the limitations, our study provides valuable preliminary data on the changes in the biomarkers of
190 endothelial function, coagulation, and platelet activation biomarkers associated with Gam-COVID-Vac
191 vaccination. While the beneficial impact of COVID-19 vaccines in controlling the pandemic is
192 undeniable, their association with a rare but severe prothrombotic state warrants further exploration,
193 paying a particular attention to the role of vaccine-induced persistent endothelial activation.

194 **Declarations**

195 **Ethics approval and consent to participate**

196 All study procedures were approved by the Research Ethics Board of Karaganda Medical
197 University under Protocol #18 from 12.04.2021. Written informed consent was obtained from all
198 participants.

199

200 **Consent for publication**

201 Authors provide consent for the publication of the manuscript detailed above, including any
202 accompanying images or data contained within the manuscript.

203

204 **Availability of data and materials**

205 The source data for all analyses will be made available with the article. Any additional data from

AdV5/AdV26 COVID vaccine and thrombosis biomarkers

206 this study will be made available, wherever possible, on appropriate request to the corresponding
207 author.

208 **Authors contributions.**

209 AT: Conceptualization, Funding acquisition, Project administration, Resources, Supervision,
210 Writing- original draft, Writing - review and editing. SY: Conceptualization, Data curation,
211 Formal analysis, Investigation, Methodology, Supervision, Validation, Visualization, Writing-
212 original draft, Writing - review and editing. IIK: Data curation, Formal analysis, Investigation,
213 Writing- original draft, Writing - review and editing. VB: Investigation. SK: Formal analysis,
214 Investigation. DK: Funding acquisition, Project administration, Resources, Supervision, Writing-
215 original draft, Writing - review and editing. ZhZh: Investigation, Resources. AP: Investigation.
216 LA: Investigation. RB: Investigation, Resources. GH: Conceptualization, Formal analysis,
217 Investigation, Writing- original draft, Writing - review and editing. DB: Conceptualization, Data
218 curation, Formal analysis, Investigation, Methodology, Visualization, Writing- original draft,
219 Writing - review and editing. MSM- Conceptualization, Methodology, Supervision, Validation,
220 Visualization, Writing - review and editing. DV: Conceptualization, Writing- original draft,
221 Writing - review and editing. IK: Conceptualization, Data curation, Formal analysis, Funding
222 acquisition, Investigation, Methodology, Project administration, Resources, Supervision,
223 Visualization, Writing- original draft, Writing - review and editing. All authors had full access to
224 all the data in the study and the lead authors (SY, IK, DV) had final responsibility for the
225 decision to submit manuscript for publication.

226 All authors read and approved the final manuscript.

227 **Acknowledgements**

228 We thank all the participants and clinical and laboratory staff, who have been involved in the

AdV5/AdV26 COVID vaccine and thrombosis biomarkers

229 study.

230 **Supplementary information**

231 All supplementary information can be found in the Appendix.

232

233 **References**

234 1. Cari L, Naghavi Alhosseini M, Bergamo A, Pacor S, Pierno S, Sava G, et al. Thrombotic events with or
235 without thrombocytopenia in recipients of adenovirus-based COVID-19 vaccines. *Front Cardiovasc Med.*
236 2022;9: 967926. doi:10.3389/fcvm.2022.967926

237 2. Gorog DA, Storey RF, Gurbel PA, Tantry US, Berger JS, Chan MY, et al. Current and novel
238 biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19
239 Thrombosis Biomarkers Colloquium. *Nat Rev Cardiol.* 2022;19: 475–495. doi:10.1038/s41569-021-
240 00665-7

241 3. Herrera-Comoglio R, Lane S. Vaccine-induced immune thrombocytopenia and thrombosis after the
242 Sputnik V vaccine. *N Engl J Med.* 2022;387: 1431–1432. doi:10.1056/NEJMc2210813

243 4. Brambilla M, Canzano P, Valle PD, Becchetti A, Conti M, Alberti M, et al. Head-to-head comparison
244 of four COVID-19 vaccines on platelet activation, coagulation and inflammation. The TREASURE study.
245 *Thromb Res.* 2023;223: 24–33. doi:10.1016/j.thromres.2023.01.015

246 5. de Laat B, Stragier H, de Laat-Kremers R, Ninivaggi M, Mesotten D, Thiessen S, et al. Population-
247 wide persistent hemostatic changes after vaccination with ChAdOx1-S. *Front Cardiovasc Med.* 2022;9:
248 966028. doi:10.3389/fcvm.2022.966028

249 6. Ostrowski SR, Sogaard OS, Tolstrup M, Stærke NB, Lundgren J, Østergaard L, et al. Inflammation and
250 platelet activation after COVID-19 vaccines - possible mechanisms behind vaccine-induced immune
251 thrombocytopenia and thrombosis. *Front Immunol.* 2021;12: 779453. doi:10.3389/fimmu.2021.779453

252 7. Petite E, Colonna E, Falcinelli E, Mezzasoma AM, Cesari E, Giglio E, et al. Anti-severe acute

AdV5/AdV26 COVID vaccine and thrombosis biomarkers

- 253 respiratory syndrome coronavirus-2 adenoviral-vector vaccines trigger subclinical antiplatelet
254 autoimmunity and increase of soluble platelet activation markers. *Br J Haematol.* 2022;198: 257–266.
255 doi:10.1111/bjh.18245
- 256 8. Nabirova D, Horth R, Smagul M, Nukenova G, Yesmagambetova A, Singer D, et al. Effectiveness of
257 four vaccines in preventing SARS-CoV-2 infection in Almaty, Kazakhstan in 2021: retrospective
258 population-based cohort study. *Front Public Health.* 2023;11: 1205159. doi:10.3389/fpubh.2023.1205159
- 259 9. Yegorov S, Kadyrova I, Negmetzhanov B, Kolesnikova Y, Kolesnichenko S, Korshukov I, et al.
260 Sputnik-V reactogenicity and immunogenicity in the blood and mucosa: a prospective cohort study. *Sci*
261 *Rep.* 2022;12: 13207. doi:10.1038/s41598-022-17514-3
- 262 10. Kadyrova I, Yegorov S, Negmetzhanov B, Kolesnikova Y, Kolesnichenko S, Korshukov I, et al. High
263 SARS-CoV-2 seroprevalence in Karaganda, Kazakhstan before the launch of COVID-19 vaccination.
264 *PLoS One.* 2022;17: e0272008. doi:10.1371/journal.pone.0272008
- 265 11. Yegorov S, Goremykina M, Ivanova R, Good SV, Babenko D, Shevtsov A, et al. Epidemiology,
266 clinical characteristics, and virologic features of COVID-19 patients in Kazakhstan: A nation-wide
267 retrospective cohort study. *Lancet Reg Health Eur.* 2021;4: 100096. doi:10.1016/j.lanepe.2021.100096
- 268 12. Cohen TS, Kelly EJ, Nylander S, Bansal H, Jepson BM, Bhuyan P, et al. Serum levels of anti-PF4
269 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination. *Sci Rep.* 2022;12: 7961. doi:10.1038/s41598-022-
270 11623-9
- 271 13. Gaunt ER, Mabbott NA. The clinical correlates of vaccine-induced immune thrombotic
272 thrombocytopenia after immunisation with adenovirus vector-based SARS-CoV-2 vaccines. *Immunother*
273 *Adv.* 2021;1: ltab019. doi:10.1093/immadv/ltab019
- 274 14. Naghashzadeh F, Shafaghi S, Dorudinia A, Naji SA, Marjani M, Amin A, et al. Myocarditis following
275 rAd26 and rAd5 vector-based COVID-19 vaccine: case report. *ESC Heart Fail.* 2022;9: 1483–1486.
276 doi:10.1002/ehf2.13821
- 277 15. Othman M, Labelle A, Mazzetti I, Elbatarny HS, Lillicrap D. Adenovirus-induced thrombocytopenia:
278 the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance. *Blood.*






AdV5/AdV26 COVID vaccine and thrombosis biomarkers






279 2007;109: 2832–2839. doi:10.1182/blood-2006-06-032524

280 16. Willems LH, Nagy M, Ten Cate H, Spronk HMH, Groh LA, Leentjens J, et al. Sustained
281 inflammation, coagulation activation and elevated endothelin-1 levels without macrovascular dysfunction
282 at 3 months after COVID-19. *Thromb Res.* 2022;209: 106–114. doi:10.1016/j.thromres.2021.11.027

283 17. Abraham GR, Kuc RE, Althage M, Greasley PJ, Ambery P, Maguire JJ, et al. Endothelin-1 is
284 increased in the plasma of patients hospitalised with Covid-19. *J Mol Cell Cardiol.* 2022;167: 92–96.
285 doi:10.1016/j.yjmcc.2022.03.007

286





● No Prior COVID-19 ● Prior COVID-19